Genor Biopharma Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Genor Biopharma Holdings yıllık ortalama 26.7% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 31.7% annual. Gelirler yılda ortalama 32.1% oranında büyüyor .

Anahtar bilgiler

26.7%

Kazanç büyüme oranı

41.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.0%
Gelir büyüme oranı	32.1%
Özkaynak getirisi	-49.5%
Net Marj	-3,631.7%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10

Gelir ve Gider Dağılımı

Genor Biopharma Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:6998 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	14	-526	91	370
31 Mar 24	7	-600	108	428
31 Dec 23	0	-674	125	485
30 Sep 23	6	-637	134	495
30 Jun 23	13	-599	143	504
31 Mar 23	14	-665	180	544
31 Dec 22	16	-730	217	584
30 Sep 22	9	-800	263	610
30 Jun 22	3	-870	309	636
31 Mar 22	1	-868	307	625
31 Dec 21	0	-865	306	613
30 Sep 21	3	-1,880	299	617
30 Jun 21	7	-2,895	292	620
31 Mar 21	10	-3,086	281	721
31 Dec 20	10	-3,027	241	697
31 Mar 20	12	-590	116	480
31 Dec 19	13	-522	89	439
31 Dec 18	7	-288	22	271

Kaliteli Kazançlar: 6998 şu anda kârlı değil.

Büyüyen Kar Marjı: 6998 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 6998 kârlı değildir, ancak son 5 yılda zararlarını yılda 26.7% oranında azaltmıştır.

Büyüme Hızlandırma: 6998 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 6998 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 5.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 6998 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -49.51% ) sahiptir.

Genor Biopharma Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

Recent updates

Edding Group Company Limited agreed to acquire Genor Biopharma Holdings Limited (SEHK:6998).

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

New minor risk - Shareholder dilution

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Genor Biopharma Holdings Limited Announces China National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)

New minor risk - Share price stability

Genor Biopharma Holdings Limited Announces Board Changes

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Consensus forecasts updated

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

JHBP (CY) Holdings Limited Submits a Clinical Trial Application to the Bellberry Human Research Ethics Committee in Australia

JHBP (CY) Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

JHBP (Cy) Holdings Limited Receives Drug Approvals from the National Medical Products Administration

JHBP (CY) Holdings Limited Appoints Han Shuhua as New Chief Scientist

New 90-day high: HK$23.00

JHBP (CY) Holdings Limited has completed an IPO in the amount of HKD 2.877144 billion.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin